title: Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
abstract: The authors present here two cases of Parkinson's disease with depression refractory to SSRIs treatment, who experienced a complete remission after replacing the ongoing SSRIs with a serotonin-noradrenalin reuptake inhibitor (SNRI), milnacipran. The case reports suggest that milnacipran may be one of the treatment options for depression in patients with Parkinson's disease who had inadequate response to SSRIs. Further studies are warranted to confirm this observation.
authors.affiliation: Department of Neuropsychiatry, Akita University School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan. hito_takahashi@hotmail.com
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Kamata
authors.forename: Keizo
authors.initials: K
authors.lastname: Yoshida
authors.forename: Hisashi
authors.initials: H
authors.lastname: Higuchi
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Shimizu
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D003521:Cyclopropanes / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078764:Milnacipran; D010300:Parkinson Disease / Q000150:complications*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
chemical_list: D018759:Adrenergic Uptake Inhibitors; D003521:Cyclopropanes; D000078764:Milnacipran; D017367:Selective Serotonin Reuptake Inhibitors